Today it is unveiling more data from that Phase III study, showing exactly how much Lucentis improved vision in AMD patients versus a placebo injection.

FORBES: Magazine Article

Recall that a few patients in the phase III study presented last fall at ACR also experienced heart failure, but that TNFs are also associated with heart failure.

FORBES: Pfizer's Key Drug Walks A Tightrope

In the first stage of a phase III study called CLL11, the drug in combination with chemotherapy significantly reduced the risk of disease worsening or death compared to chemotherapy alone in previously untreated patients.

FORBES: Roche's Worth $58 On Continued Growth And Strong Pipeline